Tuesday, April 07, 2020 11:28:59 AM
ROCKVILLE, Md. and BEIJING, April 7, 2020 - CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that Dr. Wei-Wu He, Chairman & CEO will present an overview of the company and provide a business update at the Solebury Trout Virtual Global Healthcare Series. During the 25-minute presentation, participants will be able to submit questions electronically with answers provided by the discretion of the company on an individual basis afterwards. Details are as follows:
Date/Time: Tuesday, April 7, at 11:00a.m./p.m. EDT
To access the presentation, please login at: https://78449.themediaframe.com/dataconf/productusers/solebury/mediaframe/36850/indexl.html
Webcast archive: 24 hours following the presentation an archive of the event will be available on the Company’s website at https://www.casipharmaceuticals.com/
Recent CASI News
- CASI PHARMACEUTICALS REPORTS DEVELOPMENT RELATING TO ITS DISPUTES WITH JUVENTAS • PR Newswire (US) • 04/08/2024 09:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2023 BUSINESS AND FINANCIAL RESULTS • PR Newswire (US) • 03/28/2024 11:00:00 AM
- CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China • PR Newswire (US) • 03/05/2024 12:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES FIRST DOSING OF FOLOTYN® IN CHINA • PR Newswire (US) • 02/16/2024 12:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 BUSINESS AND FINANCIAL UPDATES • PR Newswire (US) • 11/14/2023 12:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES MARKET APPROVAL OF CNCT19 BY CHINA NMPA • PR Newswire (US) • 11/08/2023 12:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES • PR Newswire (US) • 08/11/2023 11:00:00 AM
- Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals • PR Newswire (US) • 08/01/2023 11:00:00 AM
- CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339 • PR Newswire (US) • 07/20/2023 12:00:00 PM
- CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS • PR Newswire (US) • 05/17/2023 11:35:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM